<DOC>
	<DOCNO>NCT00100724</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity rPA102 vaccine give intramuscularly 0 4 week 2 dose range 4 adjuvant level .</brief_summary>
	<brief_title>Trial rPA-102 Vaccine Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Able understand study give write informed consent . A sign informed consent must place initiation study intervention . Healthy male female age 1855 year old ( inclusive ) without significant physical clinical laboratory abnormality . Two intact upper arm sufficient intramuscular ( IM ) tissue deltoid region vaccine administration . For female , negative serum pregnancy test screening agreement use adequate birth control first 2 month study . Willingness ability return followup visit blood draw duration study . Willingness complete Volunteer Diary report concomitant medication adverse event ( AEs ) study site monitor study period . Prior history , know exposure form B. anthracis anthrax immunization . Member Armed Services ( Active Duty Reserve ) since 1990 , history previous anthrax vaccination . Employment industry involve contact ruminant animal , veterinary science , exposure B. anthracis , emergency first responder . Expected noncompliant study visit plan move within 12 month . Body mass index &gt; 35 &lt; 19 . Known allergy aluminum hydroxide , kanamycin , aminoglycoside antibiotic ( gentamicin ) . Pregnancy ( positive urine pregnancy test within 24 hour prior vaccination ) , lactation . HIV positive ( history screen ELISA ) . Hepatitis B C positive ( history screen HBsAg/antiHCV ELISA ) . Active past internal organ , hematologic malignancy , metastatic cutaneous malignancy . History , current autoimmune disease , include limited systemic lupus erythematosus , scleroderma , polyarteritis . Immunodeficiency unstable medical condition determine baseline medical history , physical exam , laboratory assessment . Received plan receive license live vaccine within 30 day study vaccination . Received plan receive license kill vaccine within 14 day study vaccination . Received plan receive immunoglobulin blood product within 60 day study vaccination . Received plan receive experimental drugs/vaccines within 30 day prior , duration study . Received plan receive systemic immunosuppressive therapy , radiation therapy , highdose inhaled steroid within 30 day study vaccination . Use systemic chemotheraphy within 5 year prior study . History GuillainBarre Syndrome . In addition condition list , follow may qualify reason exclude volunteer study : fever along moderate serious illness within 3 day vaccination condition , opinion investigator , would render vaccination unsafe would interfere study evaluation . Pending resolution symptom , volunteer may reconsider vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Anthrax</keyword>
	<keyword>rPA102</keyword>
	<keyword>vaccine</keyword>
</DOC>